Genzyme vet David Meeker takes helm at stealthy KSQ with $76M and a new map for drug discovery
David Meeker left Genzyme last April after a 23-year run, including six years as president after Sanofi stepped in to buy the landmark biotech six years ago. And as it turns out, instead of retiring and ending the story, his career was shifting into a brand new chapter.
Today, five months later, after adding a string of biotech board positions to his schedule, Meeker has landed his next big gig in biotech. And like many of his colleagues ahead of him, he’s transitioning from his formal exit from the Big Pharma world to the thriving cosmos of biotech startups.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.